Doctors' and patients' preferences for participation and treatment in curative prostate cancer radiotherapy

被引:58
|
作者
Stalmeier, Peep F. M.
van Tol-Geerdink, Julia J.
van Lin, Emile N. J. Th.
Schimmel, Erik
Huizenga, Henk
van Daal, Willem A. J.
Leer, Jan-Willem
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Radiat, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Oncol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Med Technol Assessment, NL-6500 HB Nijmegen, Netherlands
[4] Arnhems Radiotherapeut Inst, Arnhem, Netherlands
关键词
D O I
10.1200/JCO.2006.07.4955
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Physicians hold opinions about unvoiced patient preferences, so-called substitute preferences. We studied whether doctors can predict preferences of patients supported with a decision aid. Methods A total of 150 patients with prostate cancer facing radiotherapy were included. After the initial consultation, without discussing any treatment choice, physicians gave substitute judgments for patients' decision-making and radiation dose preferences. Physicians knew that several weeks later, patients would be empowered by a decision aid supporting a choice between two radiation doses involving a trade-off between disease-free survival and adverse effects. Subsequently, patient preferences for decision making ( whether or not they wanted to choose a radiation dose) and for treatment ( low or high dose) were obtained. The chosen radiation dose actually was administered. Results Of the patients studied, 79% chose a treatment; physicians believed that 66% of the patients wanted to choose. Agreement was poor ( 64%; kappa = 0.13; P = .11), and was better as patients became more hopeful ( odds ratio [ OR] = 4.4 per unit; P = .001) and as physicians' experience increased ( OR = 1.09 per year; P = .02). Twenty percent of physicians' preferences, 51% of physicians' substitute preferences, and 71% of patients' preferences favored the lower dose; agreement was again poor ( 70%; kappa = 0.2; P = .03). Conclusion Physicians had problems predicting the preferences of patients empowered with a decision aid. They slightly underestimated patients' decision-making preferences, and underestimated patients' preferences for the less toxic treatment. Counseling might be improved by first informing patients-possibly using a decision aid-before discussing patient preferences.
引用
收藏
页码:3096 / 3100
页数:5
相关论文
共 50 条
  • [21] Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy
    Saelen, Marie G.
    Hjelle, Line V.
    Aarsaether, Erling
    Knutsen, Tore
    Andersen, Sigve
    Bentzen, Anne G.
    Richardsen, Elin
    Fossa, Sophie D.
    Haugnes, Hege S.
    ACTA ONCOLOGICA, 2023, 62 (06) : 657 - 665
  • [22] CURATIVE RADIOTHERAPY FOR CARCINOMA OF THE PROSTATE
    DELREGATO, JA
    CANCER DETECTION AND PREVENTION, 1979, 2 (04): : 773 - 784
  • [23] PROSTATE CARCINOMA - CURATIVE RADIOTHERAPY
    KNUFERMANN, H
    WANNENMACHER, M
    BULLETIN DU CANCER, 1985, 72 (06) : 568 - 572
  • [24] Localized Prostate Cancer Patients' Preferences for Hypofractionated Radiotherapy: A Discrete Choice Experiment
    Sigurdson, S.
    Harrison, M.
    Pearce, A.
    Richardson, H.
    Zaza, K.
    Brundage, M. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S145 - S145
  • [25] COST EFFECTIVENESS OF PROSTATE CANCER CURATIVE TREATMENT AMONG YOUNGER PATIENTS
    Jayadevappa, Ravishankar
    Chhatre, Sumedha
    Wein, Alan J.
    Malkowicz, S. Bruce
    JOURNAL OF UROLOGY, 2009, 181 (04): : 195 - 195
  • [26] Rectal bleeding after curative intended radiotherapy for prostate cancer
    Schaldemose, Ellen L.
    Fokdal, Lars U.
    Zedan, Ahmed H.
    Bentzen, Lise N.
    Berg, Martin
    Nissen, Henrik D.
    Mortensen, Bjarke
    Madsen, Christine V.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S2599 - S2601
  • [27] Significant interruptions in radiotherapy during curative treatment for prostate cancer are correlated with poorer oncological outcomes
    Tomaciello, Miriam
    Sciurti, Antonio
    Caprara, Luisa
    Conte, Miriam
    Frantellizzi, Viviana
    De Vincentis, Giuseppe
    Zaccaro, Lucy
    Cunicella, Giorgia
    Fallico, Alberto
    Cattaneo, Carlo Guglielmo
    Lisi, Roberto
    Arcieri, Silvia
    Albanese, Carlina Veneranda
    Tini, Paolo
    Detti, Beatrice
    Di Cataldo, Vanessa
    Mangoni, Monica
    Francolini, Giulio
    Migliara, Giuseppe
    Livi, Lorenzo
    De Felice, Francesca
    Minniti, Giuseppe
    Gravina, Giovanni Luca
    Baccolini, Valentina
    Marampon, Francesco
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2025,
  • [28] Pretreatment plasma osteopontin level as a marker of response to curative radiotherapy and hormonal treatment for prostate cancer
    Smolska-Ciszewska, Beata
    Mrochem-Kwarciak, Jolanta
    Karczmarczyk, Katarzyna
    Deja, Regina
    Suwinski, Rafal
    RADIOTHERAPY AND ONCOLOGY, 2024, 200
  • [29] Options for Curative Treatment of Localized Prostate Cancer
    Knipper, Sophie
    Ott, Saskia
    Schlemmer, Heinz-Peter
    Grimm, Marc-Oliver
    Graefen, Markus
    Wiegel, Thomas
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2021, 118 (13): : 228 - +
  • [30] Evaluation of inflammatory cytokines and oxidative stress markers in prostate cancer patients undergoing curative radiotherapy
    Abdel-Messeih, Phebe L.
    Nosseir, Neveen M.
    Bakhe, Osama H.
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2017, 42 (01) : 68 - 72